Mycotopia Therapies, Inc.
TPIA · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.01 | 0.11 | 0.00 |
| FCF Yield | -1.16% | -4.44% | -2.69% | -9.45% |
| EV / EBITDA | -31.93 | -10.06 | -2.01 | -3.83 |
| Quality | ||||
| ROIC | -47.24% | -30.41% | -41.87% | 23.35% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 50.00% |
| Cash Conversion Ratio | 0.34 | 0.34 | 0.05 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 873,806.33% | 873,806.33% | 873,806.33% | 872,852.49% |
| Free Cash Flow Growth | -8.60% | -480.25% | -64.30% | 77.74% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | 0.21 | -0.02 | -3.28 |
| Interest Coverage | 43.07 | -5.15 | -8.55 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -76.67 |